SGP SpyGlass Pharma, Inc.
Mergers ·
The cash deal brings in house the company that makes the intraocular lens used in both of SpyGlass's Phase 3 glaucoma trials. The seller, Santen, gets an exclusive right to sell AVS's Eternity lenses in Japan.
Second-quarter net loss was $19.9 million. SpyGlass says its IPO proceeds and cash will fund operations through 2028 and that it will need substantial additional funding after that.
Defendants are SpyGlass Pharma and employee Long Doan. SpyGlass countersued Glaukos on May 22 over contract interference, and the court moved trial to January 2027.
SpyGlass Pharma closed a $172.5 million IPO with Jefferies, Leerink Partners, Citigroup and Stifel running the book. The money is meant to carry a glaucoma implant through two Phase 3 trials.
| Line | FY2025 | FY2024 |
|---|---|---|
| Research and development | $29.2 million | $20.0 million |
| Net income (loss) | -$39.9 million | -$29.2 million |
| Cash from operations | -$32.7 million | -$22.0 million |
| Cash and equivalents | $96.4 million | $16.3 million |
Our latest story on this, dated Aug 6, 2026: "SpyGlass ends June with $234.2 million and says cash lasts through 2028". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated May 22, 2026: "SpyGlass countersues Glaukos in trade-secret case; trial moved to January 2027". The story links the filing or release it is based on. Read the story.
SpyGlass Pharma, Inc. trades under the ticker SGP on NASDAQ.
SpyGlass Pharma, Inc. is listed on NASDAQ.
The SEC Central Index Key (CIK) for SpyGlass Pharma, Inc. is 1778922. Its filings are on SEC EDGAR.
33,447,979 shares as of 2026-07-29, per the cover page of its 10-Q filed 2026-08-06.
Our directory records SpyGlass Pharma, Inc. under United States.
Our directory classifies SpyGlass Pharma, Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline.
The ISIN recorded for SpyGlass Pharma, Inc. is US85220G1094.
aibio.space lists SpyGlass Pharma, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as DE.
SpyGlass Pharma, Inc. reported a net loss of $39.9 million for the fiscal year ended Dec 31, 2025, and used $32.7 million of cash in operations, per its annual report to the SEC.
$29.2 million in the fiscal year ended Dec 31, 2025, per its annual report.
$223.1 million in cash at Jun 30, 2026, per its 10-Q.
Our latest story on SpyGlass Pharma, dated Oct 1, 2026: "SpyGlass buys lens maker Advanced Vision Science from Santen for about $13 million". The cash deal brings in house the company that makes the intraocular lens used in both of SpyGlass's Phase 3 glaucoma trials. The seller, Santen, gets an exclusive right to sell AVS's Eternity lenses in Japan. Source.
SpyGlass closed the acquisition of its lens supplier for a $13 million base purchase price subject to adjustments. Source
The annual report disclosed the March 2025 Series C-2 closing of approximately $50 million; no exact closing day is supplied. Source
The IPO closed with the underwriters option fully exercised. Source
Reported a financing. SEC Form 424B4. Source
Habib Dable joined the board in connection with the IPO. Source
SpyGlass implemented a one-for-5.7329 reverse split before its IPO. Source
Filed a registration statement for a share offering. SEC Form S-1. Source
SpyGlass filed a private-offering notice reporting $74,999,989 sold. Source
The private-offering notice identifies the first sale date; its reported total is dated to that notice. Source
At 2026-06-30, SpyGlass reported $223.143 million cash and equivalents and $11.043 million short-term investments. These are dated financial-statement balances. Source
The quarterly report projected operating-expense and capital-expenditure funding through 2028. It is a management forecast, not a guaranteed cash exhaustion date. Source
No substantial-doubt statement was found in the opened quarterly report. Management instead states sufficient liquidity for the next twelve months, while acknowledging future financing risks. Source
The completed IPO produced $172.5 million gross, including the full underwriters option, before underwriting and other offering costs. Source
A one-for-5.7329 split became effective on 2026-01-28 before the IPO. The source describes a capitalization adjustment, not an exchange deficiency cure. Source
The company acquired all outstanding equity of Advanced Vision Science, Inc., its existing lens supplier. The base price was $13 million, subject to closing adjustments. Source
The disclosed case concerns trade-secret and related claims against SpyGlass and an employee, not a disclosed shareholder class action. SpyGlass denies the allegations and has filed counterclaims. Source
The report states that the original trial date was extended to 2027-01-26. No current docket confirmation of that date was obtained. Source
No. It covers shares subject to awards or reserved for future plan issuance, rather than announcing completed investor subscriptions. Source
No. Fund and control-person reports can describe the same underlying purchase. The annual ownership table likewise attributes overlapping interests to affiliated directors. Source
Deloitte & Touche LLP signed the annual audit and states service since 2025. No complete earlier auditor-change chronology was verified. Source
The IPO closing release identifies the Nasdaq Global Select Market. Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio